Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants
February 02, 2023 21:54 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (Avalo) announced today the pricing of an underwritten public offering of 3,770,000 shares of...
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants
February 02, 2023 16:01 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”) announced today that it has commenced a proposed underwritten public offering of...
Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
January 17, 2023 07:00 ET
|
Avalo Therapeutics
Topline data expected in the second quarter of 2023 WAYNE, Pa. and ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that it completed...
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 07, 2022 07:30 ET
|
Avalo Therapeutics
Topline data expected in the first half of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA)Entered into agreement to sell future economic rights to previously out-licensed...
Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million
November 07, 2022 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement to sell its economic rights to future...
Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage
September 06, 2022 07:00 ET
|
Avalo Therapeutics
Strategy focused on LIGHT-signaling network targets WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) announced today that its human B and T...
Avalo to Present at the H.C. Wainwright Global Investment Conference
September 01, 2022 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will...
Avalo Therapeutics Announces Board Changes
August 11, 2022 16:01 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that on August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice...
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 04, 2022 07:30 ET
|
Avalo Therapeutics
Transferred anti-IL 18 monoclonal antibody product (AVTX-007) to Apollo Therapeutics in July with the approximate $15 million of upfront payment received in AugustDosed first patient in the Phase 2...
Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)
August 02, 2022 07:30 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced the first patient has been dosed in the pivotal LADDER trial (A Phase 3,...